Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema

Author(s): Tobias P. H. Nissen*, Henrik Vorum, Kristian Aasbjerg

Journal Name: Current Drug Safety

Volume 16 , Issue 1 , 2021

Become EABM
Become Reviewer
Call for Editor


Proliferative diabetic retinopathy and diabetic macular edema can be a potentially sightthreatening disease if not treated correctly. It is directly correlated to the duration of diabetes and how well managed the patients' diabetes is. In the last 15 years, the treatment of diabetic eye disease has taken a quantum leap in methodology due to the group of biological agents named antivascular endothelial growth factor (anti-VEGF). The introduction of the first biological agent has revolutionized the treatment, not only in diabetic eye disease but also across most inflammatory eye diseases, causing leakage of fluid from the blood vessels i.e., in age-related macular degeneration. The availability of these biological agents, despite their considerable costs, have significantly improved the outcomes measured in visual acuity compared to more traditional treatments of diabetic retinopathy in the form of sole laser treatment and glycemic control. The agents demonstrate a favorable safety profile, but if the rarest and most severe side effects occur, there is a potential total loss of vision.

This review aims to make an overview of the current pharmaceutical therapeutic options in the treatment of diabetic macular edema. This includes laser therapy, intravitreal steroids, and a primary focus on intravitreal antivascular endothelial growth factors.

Keywords: Diabetic macular edema, anti-VEGF, laser, corticosteroids, safety profile, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 12 March, 2021
Page: [17 - 31]
Pages: 15
DOI: 10.2174/1574886315666200902154322
Price: $65

Article Metrics

PDF: 19